Micron Technology, Inc. vs TransMedics Group Inc — how do they compare? Micron Technology, Inc. trades at $985.12 (market cap $977.44B), while TransMedics Group Inc trades at $74.3 (market cap $2.54B). The key difference: Micron Technology, Inc. is far larger — about 384.8× TransMedics Group Inc's market cap, and Micron Technology, Inc. pays a 0.06% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| MU | TMDX | |
|---|---|---|
Market Cap | $977.44B | $2.54B |
Sector | Technology | Technology |
52-Week High | $1.21K | $150.42 |
52-Week Low | $104.88 | $61.99 |
Enterprise Value | $957.80B | $2.94B |
Dividend Yield | 0.06% | — |
Signals from Pluang's Aura AI — not financial advice
Micron Technology (MU) surged 14.36% to $970.82, driven by strong AI memory demand and positive analyst sentiment. The stock shows robust fundamentals with a P/E of 19.56 and net income margin of 55.91%, supported by three consecutive quarterly earnings beats. Technical indicators are mixed, with a bearish moving average signal but oversold RSI levels suggesting potential rebound. Recent news highlights AI-driven memory chip demand and strategic customer agreements fueling growth optimism.
Outlook remains bullish due to AI super-cycle tailwinds and projected 2026 revenue of $90.3B, though risks include cyclical semiconductor demand and high valuation multiples. Analyst consensus strongly favors Buy with a $1,550 price target, indicating ~60% upside potential from current levels.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →